On Monday, the World Health Organization(WHO) gave emergency usage authorization for AstraZeneca’s Covid-19 vaccines, enabling delivery to begin in some of the poorest countries in the world.
On Monday (local time), the World Health Organization (WHO) gave permission for emergency use (EUA) for two versions of AstraZeneca-Oxford-developed COVID-19 vaccinations, enabling these vaccinations to be carried out worldwide by COVAX. AstraZeneca-SKBio (Republic of Korea) and the Serum Institute of India are developing the vaccines. EUL of the WHO assesses the quality, safety and effectiveness of vaccines for COVID-19. It also helps countries to step up their own regulatory clearance for COVID-19 vaccines to be imported and delivered.
Dr. Mariângela Simão, WHO Assistant Director-General for Access to Medicine and Health Goods, said: “Countries with no access to vaccines to date will finally be able to start vaccinating their health workers and populations at risk, contributing to the COVAX Facility’s goal of equitable vaccine distribution,”
He announced that the listing was finished in less than four weeks from the time the manufacturers obtained the full reports from WHO.
The WHO EUL method can be carried out easily when vaccine developers send in a timely manner the complete data requested by the WHO. If these data are submitted, the WHO will be able to immediately mobilize its appraisal team and regulators from around the world to review the details and, if necessary, carry out production site inspections.
On 8 February, the WHO Strategic Advisory Committee of Experts on Immunization (SAGE) reviewed the vaccine and made guidelines for the use of vaccines in populations (i.e. recommended age groups, intervals between shots, advice for specific groups such as pregnant and lactating women). The vaccine was recommended by SAGE for all age groups of 18 and over.